Troglitazone

Biological Activity

Troglitazone is a selective PPARγ receptor agonist (EC₅₀ values are 780 and 555 nM at murine and human PPARγ receptors respectively). Displays no activity at PPARα or PPARδ receptors. Antidiabetic agent; exerts potent glucose-lowering effects in insulin-resistant diabetic mice. Displays anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Also inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Acute effects of troglitazone on in vivo Ins action in normal rats.
   Lee and Olefsky
   Metabolism, 1995;44:1166
2. Ligand type-specific interactions of peroxisome-proliferator-activated receptor γ with transcriptional coactivators.
   Kodera et al.
   J.Biol.Chem., 2000;275:33201
3. The PPARs: from orphan receptors to drug discovery.
   Willson et al.
   J.Med.Chem., 2000;43:527
4. Effects of troglitazone on the growth and differentiation of hematopoietic cell lines.
   Fujimura et al.
   Int.J.Oncol., 1998;13:1263

Product Datasheets